The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | The inclusion of patients with brain metastases in clinical trials
Angelika Starzer, MD, Medical University of Vienna, Vienna, Austria, discusses the significance of including patients with brain metastases in clinical trials. Historically, patients have been excluded from trials, however, real-world data has demonstrated an abundance of patients with various cancers develop brain metastases, highlighting the importance of including this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
